SEC Comment Letter for Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Feb 27, 2018
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: Feb. 27, 2018 · CIK: 0001649989 · Accession: 0000000000-18-006269
AI Filing Summary & Sentiment
File numbers found in text: 333-223063
Letter
February 26, 2018 Lawrence A. Kenyon Chief Financial Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, New Jersey 08512 Re:Oncobiologics, Inc. Registration Statement on Form S-3 Filed February 15, 2018 File No. 333-223063 Dear Dr. Kenyon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Marianne Sarrazin - Cooley LLP
Show Raw Text
February 26, 2018
Lawrence A. Kenyon
Chief Financial Officer
Oncobiologics, Inc.
7 Clarke Drive
Cranbury, New Jersey 08512
Re:Oncobiologics, Inc.
Registration Statement on Form S-3
Filed February 15, 2018
File No. 333-223063
Dear Dr. Kenyon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Marianne Sarrazin - Cooley LLP